16 November 2023
SHARE NOW
ATE
Cell Therapy
Gene Therapy
Raw Materials
Strategy
This Briefing from Advanced Therapies Europe 2023, hosted by Cytiva, focusses on the implementation of process optimization and process intensification for cell and gene therapy manufacturing.
In this session, Emmanuelle Cameau, Strategic Technology Partnership Leader at Cytiva is joined by:
- Manuel Carrondo, Full Professor of Chemical and Biochemical Engineering, UNL, Vice-President, iBET
- Alessandra De Riva, Head of Process Development and R&D, Cytiva
- Marc Davies, Vice-President, R&D, Leucid Bio
- Ben Weil, Director of Manufacturing, INmune Bio
- Sofia Venceslau, Senior Project Manager, ReciBioPharm
Following an introduction by Emmanuelle, the panellists dive further into the topic at hand.
The panel begins by explaining how to reduce waste during process intensification, such as primary process flow and materials flow, and how they can be implemented in new modalities to optimize cell and gene therapy products.
More like this
20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry
Lee Buckler, SVP Advanced Therapies, Blood Centers of America, Advanced Therapies Network, reflects on two decades of working within the advanced therapies industry as Phacilitate celebrates 20 years of operating in the field.
4 December 2023
Oxford Biomedica Acquires ABL Europe from Institut Mérieux
Oxford Biomedica Acquires ABL Europe from Institut Mérieux
6 December 2023
Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome
Two female pediatric patients with Rett syndrome were the first children worldwide to receive the promising treatment with Neurogene’s lead gene therapy product.
5 December 2023
Discover more like this
